Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: A one-year follow-up controlled study

International Journal of Ophthalmology

Volumn 7, Issue 2, 2014, Pages 335-339

  Saviano, Sandro ^a   Piermarocchi, Rita ^a   Leon, Pia E ^a   Mangogna, Alessandro ^a   Zanei, Andrea ^a   Sc, Fabiano Cavarzeran ^b   Tognetto, Daniele ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bevacizumab; Combined therapy; Myopia; Neovascularization; Photodynamic therapy

Indexed keywords

EID: 84899871049     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2014.02.26     Document Type: Article

References (20)

1. Montero JA, Ruiz-MorenoJM. Treatment of choroidal neovascularization in high myopia. Current Drug Targets. 2010;ll(5):63O-644. [PubMed]
2. Parodi MB, IaconoP, Papayannis A, Sheth S, Bandel10F. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathogic myopia. Arch Ophthalmol. 2010;l28(4):437-444. [PubMed]
3. Verteporfin in PhotodynamicTherapy Study Group Photodynamictherapy of subfoveal choroidal neovascularization in pathogic myopia with verteporfin. l-year results of a randomized clinical trial-VIP report no.l. Ophthalmogy. 2001;108(5):84l-852. [PubMed]
4. Cohen SY. Anti-VEGFdrugs as the 2009 first-line therapy for choroidal neovascularization in pathogic myopia. Retina. 2009;29(8):1062-1066. [PubMed]
5. DescoMC, Mataix J, Garcia-Pous M, Palacs-PozoE, Navea A. Combined therapy: photodynamictherapy and bevacizumab to treat myopic neovascular membranes. One-year f011ow-up. Retina. 2011;3l(3):475-48l. [PubMed]
6. Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Jr., Mittra RA. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age related macular degeneration. Retina. 2008;28(5):675-68l. [PubMed]
7. Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathogic myopia. Retina. 2009;29(6):750-756. [PubMed]
8. Yamamotol, Rogers AH, Reich el E,Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathogic myopia. Br JOphthalmol. 2007591 (2) 1157-160. [PMCfree article] [PubMed]
9. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, Gabrieli CB. Choroidal neovascularization in pathogic myopia: intravitreal ranibizumab versus bevacizumab-A randomized contred trial. Am JOphthalmol. 58-464. [PubMed]
10. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 1-year results of a prospective pit study. Br JOphthalmol. 2009;93(2):l50-l54. [PubMed]
11. Potter MJ, SzaboSM, HoT. Combined photody namic therapy and intravitreal Triamcinone for the treatment of myopic choroidal neovascularization in a 13-year-old girl. Graefes Arch Clin Exp Ophthalmol. 2006;244(5):639-641. [PubMed]
12. Han DP, McAllister JT, Wei nberg DV, Kim JE, WirostkoWJ. Combined intravitreal anti-VEGFandverteporfin therapy for juxtafoveal andextrafoveal choroidal neovascularization as an alternative to 1 aser photocoagulation. Eye. 2010;24(4):7l3-7l6. [PubMed]
13. Voyokov B, Gelisken F, Inhoffen W, Voelker M, Ulrich Bartz-Schmidt K, Ziemssen F. Bevacizumab for choroidal neovascularization secondary to pathogic myopia: is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol. 2010;248(4):543-550. [PubMed]
14. Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina. 2010;3o(3):4l8-424. [PubMed]
15. Hay as hi K, Ohno-Matsui K, Shimada N, Moriyama M, Hara W, Yoshida T, TokoroT, Mochizuki M. Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photody namic therapy. Graefes Arch Clin Exp Ophthalmol. 2009;247(s):6o9-6l8. [PubMed]
16. IkunoY, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, TanoY. Intravitreal bevacizumab for choroidal neovascularization attributable to pathogical myopia: one-year results. Am JOphthalmol. 20095147(1) :94-100. el. [PubMed]
17. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathogic myopia: 12-month results. Am JOphthalmol. 2009;l4(l):84-93.el. [PubMed]
18. Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathogic myopia: systematic review and meta-Analysis. Retina. 2013;33(7):l375-l392. [PubMed]
19. Wakabayashi T, IkunoY, Gomi F. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathogic myopia. Retina. 2011;3l(5):88o-886. [PubMed]
20. Lai TY, Luk FO, LeeGK, Lam DS. ng-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye. 2012;26(7):l004-l0ll. [PMCfreearticle] [PubMed]